> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Panel to Review Insmed Lung Disease Drug
- URL: https://www.fdaweb.com/panel-to-review-insmed-lung-disease-drug/
- Published: 2018-07-09T12:00:00.000Z
- Updated: 2026-09-15T00:17:57.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5141811

*Federal Register* notice: FDA has announced an 8/7 Antimicrobial Drugs Advisory Committee meeting. Panel members will discuss an Insmed NDA for amikacin liposome inhalation suspension, indicated for treating nontuberculous mycobacterial lung disease caused by Mycobacterium avium complex in adults as part of a combination antibacterial drug regimen. To view the notice, click [here](https://www.gpo.gov/fdsys/pkg/FR-2018-07-03/pdf/2018-14240.pdf?ref=fdaweb.com).